Navigation Links
YM BioSciences raises US$3.2 million in support of JAK 1/2 program

-Proceeds to support acceleration of CYT387 Phase II myelofibrosis study-

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced today that it has raised approximately US$3.2 million through a non-brokered private placement of 2,500,000 common shares to be issued at US$1.27. The sale price is at no discount to the closing price of the shares on the NYSE Amex on June 1, 2010. Listing of the common shares sold has been approved by the NYSE Amex and conditionally approved by the Toronto Stock Exchange (TSX) subject to the Company fulfilling all the requirements of the TSX. The investment was made by a leading international health-care-specific investment fund management company recognizing the increased demands on YM's cash resources from the recently announced expansion by the Company into the earlier-than-planned Phase II component of its trial at Mayo Clinic with CYT 387 in myelofibrosis.

"The recent decision by the company to accelerate the current Phase I/II clinical trial of CYT387 in myelofibrosis through an earlier-than-planned initiation of the Phase II component supports our belief that CYT387 has excellent potential for clinical success," said David Allan, Chairman and CEO of YM BioSciences. "We anticipate that headline safety and tolerability data from the Phase I arm of this study will be available in the next quarter with preliminary Phase II data expected to be submitted for presentation at the American Society of Hematology conference late in 2010. The company is also exploring opportunities for significant further expansion of the program, in light of the favourable findings to date."

The previously announced expansion will allow for more patients to be dosed during 2010, in turn allowing more rapid and innovative selection of doses for registration-enabling Phase III studies in myelofibrosis. Since JAK 1/2 inhibitors have broad therapeutic applicability with prospects in numerous indications beyond myelofibrosis, including oncology and autoimmune diseases, YM, in addition to the expansion of this trial, is planning for the development of CYT387 in hematology, and oncology indications with unmet medical needs.

An April 19, 2010 paper, (Jeffrey W. Tyner, Michael W. Deininger et al) published in the premier hematology journal Blood, described an extensive body of work demonstrating the potent activity of CYT387 in in vitro cell assays and in an in vivo model of the myeloproliferative neoplasms and a recent internal study at YM BioSciences has been reported to demonstrate that CYT387 possesses similar potency against JAK1/2 enzymes as INCB18424. Moreover, in the same study CYT387 was demonstrated to have improved selectivity over JAK3 and TYK2 than INCB18424, which would be expected to result in a superior therapeutic window for CYT387.

CYT387 was acquired by YM BioSciences through merging the Australian biotechnology company, Cytopia Ltd. into YM in early 2010. The founder of Cytopia, Dr. Andrew Wilks, discovered the JAK1 and JAK2 enzymes and his seminal work led to the discovery and subsequent development of CYT387. The company also holds patents over the enzyme targets of JAK1 and JAK2, and intellectual property over the JAK2 crystal structure. The YM compound has been shown to possess excellent JAK 1/2 potency and selectivity in a panel of assays.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company. Together with the products from YM BioSciences Australia, YM is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT387, a JAK 1/2 small molecule inhibitor; CYT997, a potent, vascular disrupting agent (VDA); and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
2. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
3. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
4. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
5. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
6. YM BioSciences third quarter 2010 operational and financial results
7. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
8. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
9. YM BioSciences announces controlled equity offering
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
11. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
Post Your Comments:
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... metabolism. But unless it is bound to proteins, copper is also toxic to ... researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader ... five states to develop and pitch their BIG ideas to improve health and wellness ... competing for votes to win the title of SAP's Teen Innovator, an all-expenses paid ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna ... announced today that the remaining 11,000 post-share consolidation ... Purchase Warrants (the "Series B Warrants") subject to ... exercised on November 23, 2015, which will result ... After giving effect to the issuance of such ...
Breaking Biology Technology:
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 ... is dominated by a few companies, according to Kalorama ... own 51% of the market share of the 6.1 ... The World Market for Molecular Diagnostic s . ... "The market is still controlled by one company and ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/12/2015)... LONDON , Nov. 11, 2015   ... and reliable analytical tools has been paving the ... and qualitative determination of discrete analytes in clinical, ... sensors are being predominantly used in medical applications, ... and environmental sectors due to continuous emphasis on ...
Breaking Biology News(10 mins):